Openfund

CORDIS · ACHILLES

Advancing in the CHallenge of Improving Lymphoma and LEukemia Survival

Code
ACHILLES
Programme
HORIZON
Call
MSCA Doctoral Networks 2024 HORIZON-MSCA-2024-DN-01-01
Status
SIGNED
Period
2025-12-01 – 2029-11-30
EU contribution (whole consortium)4 251 589 €
EU contribution to Bulgarian participants237 581 €

Official data · CORDIS · synced 2026-10-17 10:16 · official record

Participants

OrganisationsRoleCountryGrant
FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAScoordinatorES564 376 €
Lead Biologics International ABparticipantSE324 630 €
KAROLINSKA INSTITUTETparticipantSE324 630 €
UNIVERSITE PARIS CITEparticipantFR314 669 €
STICHTING AMSTERDAM UMCparticipantNL305 286 €
EBERHARD KARLS UNIVERSITAET TUEBINGENparticipantDE290 272 €
ONECHAIN IMMUNOTHERAPEUTICS S.L.participantES282 188 €
UNIVERSIDAD COMPLUTENSE DE MADRIDparticipantES282 188 €
UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCAparticipantIT281 755 €
I3S - INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTOparticipantPT279 445 €
ETHNIKO IDRYMA EREVNONparticipantEL269 484 €
FARMACEUTSKI FAKULTET UNIVERZITETA U BEOGRADUparticipantRS248 841 €
UNIVERSITATEA DE MEDICINA SI FARMACIE IULIU HATIEGANU CLUJ-NAPOCAparticipantRO246 243 €
ИНСТИТУТ ПО МАТЕМАТИКА И ИНФОРМАТИКАparticipantBG237 581 €
Pixelgen Technologies ABassociated partnerSE
Cobiomic Bioscience SLassociated partnerES
Fundació Internacional Josep Carrerasassociated partnerES
Sonja Nossassociated partnerDE
PANEPISTIMIO DYTIKIS ATTIKISassociated partnerEL
Saso Kocevarassociated partnerDE
Leadership Sculptor GmbHassociated partnerDE
SCIENSEED SLassociated partnerES
EUROPEAN HEMATOLOGY ASSOCIATIONassociated partnerNL
SPRINT BIOSCIENCE ABassociated partnerSE
STICHTING VUassociated partnerNL
European School of Haematologyassociated partnerFR
INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOLassociated partnerES
FUNDACIO CENTRE DE REGULACIO GENOMICAassociated partnerES
FUNDACIO PRIVADA PER A LA RECERCA I LA DOCENCIA SANT JOAN DE DEUassociated partnerES
UNIVERSIDADE DO PORTOassociated partnerPT
LUNDS UNIVERSITETassociated partnerSE
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICHassociated partnerCH
UNIVERSITAT DE BARCELONAassociated partnerES

Description

ACHILLES is a Doctoral Network (DN) program designed to train the next generation of leaders in hemato-oncology, with a focus on the development of novel therapeutic solutions for hematological malignancies. The network brings together 14 institutions from 10 EU countries and one associated state, along with partners from the biotechnology and drug discovery sectors, including two European policy leaders in hematology, the European Hematology Association (EHA) and the European School of Hematology (ESH). Through this collaboration, ACHILLES will train 16 Doctoral Candidates (DCs) to develop essential skills in experimental hemato-oncology, including the design, development, and preclinical validation of innovative therapies.ACHILLES is structured around three key scientific objectives (SOs): (1) creating novel experimental models and analytical methods, (2) exploring the oncogenic mechanisms of hematologic malignancies, and (3) developing and validating new therapies, especially targeted treatments for leukemia and lymphoma. The program will integrate cutting-edge technologies such as AI, multi-omics, and computational modeling to push the boundaries of current research and therapy development. These innovations will be applied to generate better diagnostic tools, predict treatment responses, and optimize therapeutic strategies.With a patient-centered approach, ACHILLES aims to foster both academic and industrial collaboration, bridging gaps between scientific research and clinical application. This initiative aligns with the EU's Beating Cancer Plan, with a particular focus on improving survival rates and treatment accessibility, especially in Widening Countries. Through strong academic-industrial partnerships, ACHILLES will help create a sustainable impact on the field of hemato-oncology, advancing research, therapies, and ultimately the health outcomes of leukemia and lymphoma patients worldwide.

Official data · CORDIS · synced 2026-10-17 10:16 · official record · Licence: © European Union, CC BY 4.0 (Commission reuse policy).